Democrats seek to boost FDA authority over compounders in wake of meningitis outbreak
This article was originally published in Scrip
Executive Summary
As the Centers for Disease Control and Prevention (CDC) on 9 October upped the number of US deaths to 11 related to the fungal meningitis outbreak linked to a tainted steroid compounded in Massachusetts – revealing New Jersey joined nine other states where 119 cases of the infection have now been reported – two Democrats said they planned to introduce separate pieces of legislation aimed at closing the gaps in regulating compounding pharmacies, especially those making injectable drugs.